A large investigation reported that more than half of patients receiving cellular therapies develop orthostatic hypotension, a dangerous blood pressure drop on standing, within the first month after treatment. The findings add a clinically actionable safety signal to the already complex post-cell therapy period, where clinicians commonly monitor for infection and immune complications.